Impact of COVID-19 on Parkinson's Disease Patienten Care
Summary
The COVID-19 pandemic has posed multifaceted challenges to the care of people with Parkinson’s disease. Infection with SARS-CoV-2 has been linked to transient or sustained worsening of motor and non-motor symptoms, particularly in those with advanced disease or delayed vaccination. Heightened systemic inflammation during acute illness has been associated with elevated proinflammatory markers and increased risk of severe outcomes, including prolonged hospital stays and higher mortality compared to non-Parkinson’s cohorts. Public health measures and resource reallocation disrupted routine consultations, rehabilitation and social support, giving rise to increased stress, anxiety and sleep disturbances. Rapid adoption of remote care models mitigated some access barriers but revealed stark socioeconomic disparities. Medication shortages and altered dosing regimens in resource-limited settings further compounded symptom management. These insights underscore the necessity of resilient, patient-centred healthcare frameworks that integrate preventive strategies, genetic risk assessment and equitable telemedicine solutions to safeguard long-term outcomes.
Research from Nature Portfolio
Recent studies have combined observational and genetic epidemiology to elucidate the interplay between Parkinson’s disease and COVID-19. A large cross-sectional survey reported that over 65% of people with Parkinson’s disease contracted COVID-19, with more than one third experiencing exacerbation of motor function. Key risk factors for infection included long disease duration (≥10 years) and prolonged interval since last vaccination (>12 months). Complementary Mendelian randomisation analyses demonstrated that underlying Parkinson’s disease predisposes to higher susceptibility to SARS-CoV-2 infection, while showing no direct causal effect on severity or hospitalisation. These findings highlight the importance of consistent immunisation, vigilant monitoring of high-risk patients and incorporation of genetic risk profiling into preventative care pathways.
Impact of COVID-19 on Parkinson's Disease Patienten Care publication trend
The graph below shows the total number of articles in impact of covid-19 on parkinson's disease patienten care across all publications each year (not limited to Nature Index journals).
Technical terms
Mendelian randomisation: A genetic epidemiology approach using inherited variants as instruments to infer causal links between an exposure (Parkinson’s disease) and an outcome (COVID-19 susceptibility or severity).
Cross-sectional study: An observational design that assesses the health status, exposures and outcomes of a specific population at a single point in time to identify prevalence and associations.
Telemedicine: The provision of healthcare services remotely through telecommunications technology, encompassing virtual consultations, remote monitoring and digital rehabilitation programmes.
Proinflammatory markers: Biomolecules, such as cytokines (e.g. interleukin-6) and acute-phase proteins (e.g. C-reactive protein), that signify activation of the body’s systemic inflammatory response.
References
- Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms. Translational Neurodegeneration (2023).
- SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now. Biomedicines (2023).
- COVID-19 and Parkinson’s disease: a single-center study and Mendelian randomization study. Scientific Reports (2024).
- The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study. npj Parkinson's Disease (2021).
- Clinical characteristics and outcome of COVID-19 patients with Parkinson’s disease: a hospital-based case–control study in Shanghai, China. Frontiers in Aging Neuroscience (2023).
- Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany. Movement Disorders (2021).
- The Impact of COVID‐19 on Access to Parkinson's Disease Medication. Movement Disorders (2020).
- COVID-19 Pandemic and Psychiatric Symptoms: The Impact on Parkinson's Disease in the Elderly. Frontiers in Psychiatry (2020).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.